Scot Anthony Niglio

Scot Anthony Niglio

Auto-generated profile, based on publicly available information

Scot Anthony Niglio

Memorial Sloan Kettering Cancer Center 1 Genitourinary Oncology Service, Department of Medicine New York, New York

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
HCHeather J. Chalfin
Heather J. Chalfin
TPTiziano Pramparo
Tiziano Pramparo
AMAmir Mortazavi
Amir Mortazavi
SNScot A. Niglio
Scot A. Niglio
JSJoseph D. Schonhoft
Joseph D. Schonhoft
AAAndrea Apolo
Andrea Apolo
Purpose: Circulating tumor cells (CTC) are under investigation as a minimally invasive liquid biopsy that may improve risk stratification and treatment selection. CTCs uniquely allow for digital pathology of individual malignant cell morphology and marker expression. We compared CTC features and T-cell counts with survival endpoints in a cohort of patients with metastatic genitourinary cancer treated with combination immunotherapy. Experimental Design: Markers evaluated included pan-CK/CD45/PD-L1/DAPI for CTCs and CD4/CD8/Ki-67/DAPI for T cells. ANOVA was used to compare CTC burden and T-cell populations across timepoints. Differences in survival and disease progression were evaluated using the maximum log-rank test. Results: From December 2016 to January 2019, 183 samples from 81 patients were tested. CTCs were found in 75% of patients at baseline. CTC burden was associated with shorter overall survival (OS) at baseline (P = 0.022), but not on-therapy. Five morphologic subtypes were detected, and the presence of two specific subtypes with unique cellular features at baseline and on-therapy was associated with worse OS (0.9–2.3 vs. 28.2 months; P < 0.0001–0.013). Increasing CTC heterogeneity on-therapy had a trend toward worse OS (P = 0.045). PD-L1+ CTCs on-therapy were associated with worse OS (P < 0.01, cycle 2). Low baseline and on-therapy CD4/CD8 counts were also associated with poor OS and response category. Conclusions: Shorter survival may be associated with high CTC counts at baseline, presence of specific CTC morphologic subtypes, PD-L1+ CTCs, and low %CD4/8 T cells in patients with metastatic genitourinary cancer. A future study is warranted to validate the prognostic utility of CTC heterogeneity and detection of specific CTC morphologies.

13 January 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
DGDaniel Girardi
Daniel Girardi
SNScot A. Niglio
Scot A. Niglio
AMAmir Mortazavi
Amir Mortazavi
RNRosa Nadal
Rosa Nadal
PLPrimo Lara
Primo Lara
AAAndrea Apolo
Andrea Apolo
Purpose: This study investigated the efficacy and tolerability of cabozantinib plus nivolumab (CaboNivo) in patients with metastatic urothelial carcinoma (mUC) that progressed on checkpoint inhibition (CPI). Patients and Methods: A phase I expansion cohort of patients with mUC who received prior CPI was treated with cabozantinib 40 mg/day and nivolumab 3 mg/kg every 2 weeks until disease progression/unacceptable toxicity. The primary goal was objective response rate (ORR) per RECIST v.1.1. Secondary objectives included progression-free survival (PFS), duration of response (DoR), overall survival (OS), safety, and tolerability. Results: Twenty-nine out of 30 patients enrolled were evaluable for efficacy. Median follow-up was 22.2 months. Most patients (86.7%) received prior chemotherapy and all patients received prior CPI (median seven cycles). ORR was 16.0%, with one complete response and three partial responses (PR). Among 4 responders, 2 were primary refractory, 1 had a PR, and 1 had stable disease on prior CPI. Median DoR was 33.5 months [95% confidence interval (CI), 3.7–33.5], median PFS was 3.6 months (95% CI, 2.1–5.5), and median OS was 10.4 months (95% CI, 5.8–19.5). CaboNivo decreased immunosuppressive subsets such as regulatory T cells (Tregs) and increased potential antitumor immune subsets such as nonclassical monocytes and effector T cells. A lower percentage of monocytic myeloid-derived suppressor cells (M-MDSC) and polymorphonuclear MDSCs, lower CTLA-4 and TIM-3 expression on Tregs, and higher effector CD4+ T cells at baseline were associated with better PFS and/or OS. Conclusions: CaboNivo was clinically active, well tolerated, and favorably modulated peripheral blood immune subsets in patients with mUC refractory to CPI.

2 February 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
BGBrendan Guercio
Brendan Guercio
EPEugene J. Pietzak
Eugene J. Pietzak
VRVignesh Ravichandran
Vignesh Ravichandran
JCJie-Fu Chen
Jie-Fu Chen
Ronak ShahRonak Shah
Ronak Shah
MTMin Yuen Teo
Min Yuen Teo
Purpose: Many patients with muscle-invasive bladder cancer (MIBC) are ineligible for cisplatin-based therapy. We conducted a phase II trial of neoadjuvant nivolumab ± ipilimumab for cisplatin-ineligible patients. Patients and Methods: Patients with MIBC were enrolled in two consecutive cohorts: (i) nivolumab alone and (ii) ipilimumab/nivolumab. A third cohort with alternative dosing was planned. The primary endpoint was eligibility for cystectomy ≤60 days after last treatment. Correlative analyses were performed, with the PURE-01 trial used as an independent dataset. Results: Fifteen patients enrolled onto each cohort. In cohorts 1 and 2, 12 of 15 and eight of 15 were eligible for cystectomy within 60 days, respectively. Due to cohort 2’s failure to meet the primary endpoint, cohort 3 was not initiated. With nivolumab alone, four patients achieved <ypT2ypN0 (26%), with two pathologic complete responses (pCR; 13%). With ipilimumab/nivolumab, three achieved <ypT2ypN0 (20%), with one pCR (7%). One patient after nivolumab and two after ipilimumab/nivolumab had durable clinical complete responses (CR) without cystectomy. Twelve-month recurrence-free survival (RFS) was 79% with nivolumab [95% confidence interval (CI), 61–100] and 61% with ipilimumab/nivolumab (95% CI, 39–95). Sequencing analyses suggest that NCOR1 alterations may be associated with improved clinical outcomes. Gene expression profiling indicated a potential association between tumor-infiltrating immune cells and longer RFS (log-rank P = 0.18); this was also observed in PURE-01 (P = 0.022). Conclusions: Among cisplatin-ineligible patients with MIBC, nivolumab alone was well tolerated. Ipilimumab/nivolumab caused toxicity that delayed cystectomy. Cases of progression before cystectomy indicated insufficient efficacy of pure neoadjuvant immunotherapy for unselected patients. Despite low response rates, some patients experienced sustained clinical CR without cystectomy.

31 March 2023
Verified
Other
Open access
DGDaniel Girardi
Daniel Girardi
SNScot A. Niglio
Scot A. Niglio
AMAmir Mortazavi
Amir Mortazavi
RNRosa Nadal
Rosa Nadal
PLPrimo Lara
Primo Lara
AAAndrea Apolo
Andrea Apolo
Supplementary Data from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

31 March 2023
Verified
Other
Open access
HCHeather J. Chalfin
Heather J. Chalfin
TPTiziano Pramparo
Tiziano Pramparo
AMAmir Mortazavi
Amir Mortazavi
SNScot A. Niglio
Scot A. Niglio
JSJoseph D. Schonhoft
Joseph D. Schonhoft
AAAndrea B. Apolo
Andrea B. Apolo

31 March 2023
Verified
Other
Open access
DGDaniel Girardi
Daniel Girardi
SNScot A. Niglio
Scot A. Niglio
AMAmir Mortazavi
Amir Mortazavi
RNRosa Nadal
Rosa Nadal
PLPrimo Lara
Primo Lara
AAAndrea Apolo
Andrea Apolo
Supplementary Figure from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy